These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 12601628)

  • 1. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
    Sidhu JS; Cowan D; Kaski JC
    Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
    Tack CJ; Ong MK; Lutterman JA; Smits P
    Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes.
    Aversa A; Vitale C; Volterrani M; Fabbri A; Spera G; Fini M; Rosano GM
    Diabet Med; 2008 Jan; 25(1):37-44. PubMed ID: 18199130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.
    Watts GF; Playford DA; Croft KD; Ward NC; Mori TA; Burke V
    Diabetologia; 2002 Mar; 45(3):420-6. PubMed ID: 11914748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.
    Caballero AE; Arora S; Saouaf R; Lim SC; Smakowski P; Park JY; King GL; LoGerfo FW; Horton ES; Veves A
    Diabetes; 1999 Sep; 48(9):1856-62. PubMed ID: 10480619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with Type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial.
    McSorley PT; Bell PM; Young IS; Atkinson AB; Sheridan B; Fee JP; McCance DR
    Diabet Med; 2005 Jun; 22(6):703-10. PubMed ID: 15910620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance.
    Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
    Clin Endocrinol (Oxf); 2008 May; 68(5):716-23. PubMed ID: 18070144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes.
    Vehkavaara S; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):325-30. PubMed ID: 14684428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
    Buras J; Reenstra WR; Orlow D; Horton ES; Veves A
    Obes Res; 2005 Jul; 13(7):1167-74. PubMed ID: 16076985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C.
    Antoniades C; Tousoulis D; Tountas C; Tentolouris C; Toutouza M; Vasiliadou C; Tsioufis C; Toutouzas P; Stefanadis C
    Diabet Med; 2004 Jun; 21(6):552-8. PubMed ID: 15154938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of atherosclerosis in type 2 diabetic patients by endothelial dysfunction and intima-media thickness.
    Ifrim S; Vasilescu R
    Rom J Intern Med; 2004; 42(2):343-54. PubMed ID: 15529625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
    Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
    Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.